Scientific and technological prospection of potential immunotherapies including anti-cancer vaccines with a focus on osteosarcoma
DOI:
https://doi.org/10.33448/rsd-v10i17.23015Keywords:
Immunotherapy; Osteosarcoma; Anticancer vaccines.Abstract
Osteosarcoma (OS) is a malignant bone tumor whose treatment is performed through surgical removal associated with combined chemotherapy, which include the use of medications. In order to verify the importance of immunotherapy in a scientific way, researches were carried out in order to confirm the relevance that the study presents as a technological innovation. For this, the PubMed and Science Direct article libraries were accessed to carry out a scientific prospection, a quantity of 278 and 40 with the associations of the descriptors "Bone Neoplasms AND cancer vaccines" and "Osteosarcoma AND cancer vaccines" were obtained, respectively. Regarding technological prospecting, the same descriptors were used and searches were performed in Google Patents, selecting the WO and BR offices when necessary, using the descriptors "bone neoplasms", "osteosarcoma" and "cancer vaccines", presenting a a total of 62,610, 20410 and 34337 patents, respectively for the WO office. In the BR office, 687, 613 and 585 respectively were found. Among these findings, it was possible to notice that the search for immunotherapies for OS is growing, however, the use of vaccines for OS were more present in scientific than in technological prospecting, this can be attributed to the technology of therapeutic vaccines being recent. From these results, it can be concluded that the study provided data from scientific-technological prospection, which can help direct research, highlighting the relevance of prospective technological analysis as an opportunity to invest in intellectual property as a solution to social and economic needs.
References
Argenziano, M., Tortora, C., Pota, E., Paola, A. di, Martino, M. di, Leva, C. di, Pinto, D. di, & Rossi, F. (2021). Osteosarcoma in Children: Not Only Chemotherapy. Pharmaceuticals 2021, Vol. 14, Page 923, 14(9), 923. https://doi.org/10.3390/PH14090923
Cabrera-Andrade, A., López-Cortés, A., Jaramillo-Koupermann, G., González-Díaz, H., Pazos, A., Munteanu, C. R., Pérez-Castillo, Y., & Tejera, E. (2020). A Multi-Objective Approach for Anti-Osteosarcoma Cancer Agents Discovery through Drug Repurposing. Pharmaceuticals, 13(11), 1–16. https://doi.org/10.3390/PH13110409
Chevallier, P., Saiagh, S., Dehame, V., Guillaume, T., Peterlin, P., Bercegeay, S., le Bris, Y., Bossard, C., Gauvrit, I., Dreno, B., Juge-Morineau, N., Béné, M. C., & Gregoire, M. (2021). A phase I/II feasibility vaccine study by autologous leukemic apoptotic corpse-pulsed dendritic cells for elderly AML patients. Human Vaccines & Immunotherapeutics, 17(10), 3511–3514. https://doi.org/10.1080/21645515.2021.1943991
Corre, I., Verrecchia, F., Crenn, V., Redini, F., & Trichet, V. (2020). The Osteosarcoma Microenvironment: A Complex but Targetable Ecosystem. Cells, 9(4). https://doi.org/10.3390/CELLS9040976
Cortini, M., Avnet, S., & Baldini, N. (2017). Mesenchymal stroma: Role in osteosarcoma progression. Cancer Letters, 405, 90–99. https://doi.org/10.1016/J.CANLET.2017.07.024
Chueke, G. V., & Amatucci, M. (2015). O que é bibliometria? Uma introdução ao Fórum. Internext, 10(2), 1–5. https://doi.org/10.18568/1980-4865.1021-5
del Giudice, F., Busetto, G. M., Gross, M. S., Maggi, M., Sciarra, A., Salciccia, S., Ferro, M., Sperduti, I., Flammia, S., Canale, V., Chung, B. I., Conti, S. L., Eisenberg, M. L., Skinner, E. C., & de Berardinis, E. (2021). Efficacy of three BCG strains (Connaught, TICE and RIVM) with or without secondary resection (re-TUR) for intermediate/high-risk non-muscle-invasive bladder cancers: results from a retrospective single-institution cohort analysis. Journal of Cancer Research and Clinical Oncology, 147(10), 3073–3080. https://doi.org/10.1007/S00432-021-03571-0/FIGURES/2
Erp, A. E. M. van, Versleijen-Jonkers, Y. M. H., Hillebrandt-Roeffen, M. H. S., Houdt, L. van, Gorris, M. A. J., Dam, L. S. van, Mentzel, T., Weidema, M. E., Savci-Heijink, C. D., Desar, I. M. E., Merks, H. H. M., Noesel, M. M. van, Shipley, J., Graaf, W. T. A. van der, Flucke, U. E., Meyer-Wentrup, F. A. G., van Erp, A. E. M., Versleijen-Jonkers, Y. M. H., Hillebrandt-Roeffen, M. H. S., & Meyer-Wentrup, F. A. G. (2017). Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8 + lymphocytes in primary sarcomas is subtype dependent. Oncotarget, 8(41), 71371–71384. https://doi.org/10.18632/ONCOTARGET.19071
F, J., S, J., S, S., A, N., A, S., D, R., & S, D. (2020). Osteosarcoma: A comprehensive review of management and treatment strategies. Annals of Diagnostic Pathology, 49. https://doi.org/10.1016/J.ANNDIAGPATH.2020.151654
Firnhaber, C., Swarts, A., Jezile, V., Mulongo, M., Goeieman, B., Williams, S., Faesen, M., Michelow, P., & Wilkin, T. (2021). Human Papillomavirus Vaccination Prior to Loop Electroexcision Procedure Does Not Prevent Recurrent Cervical High-grade Squamous Intraepithelial Lesions in Women Living With Human Immunodeficiency Virus: A Randomized, Double-blind, Placebo-controlled Trial. Clinical Infectious Diseases, 73(7), e2211–e2216. https://doi.org/10.1093/CID/CIAA1456
Guerra, M. R., Bustamante-Teixeira, M. T., Corrêa, C. S. L., de Abreu, D. M. X., Curado, M. P., Mooney, M., Naghavi, M., Teixeira, R., França, E. B., & Malta, D. C. (2017). Magnitude e variação da carga da mortalidade por câncer no Brasil e Unidades da Federação, 1990 e 2015. Revista Brasileira de Epidemiologia, 20, 102–115. https://doi.org/10.1590/1980-5497201700050009
Hu, G., Cheng, Z., Wu, Z., & Wang, H. (2019). Identification of potential key genes associated with osteosarcoma based on integrated bioinformatics analyses. Journal of Cellular Biochemistry, 120(8), 13554–13561. https://doi.org/10.1002/JCB.28630
IC, O., R, B., O, A., II, O., & G, A. (2021). Evaluation of possible effects of Persea americana seeds on female reproductive hormonal and toxicity profile. Journal of Ethnopharmacology, 273. https://doi.org/10.1016/J.JEP.2021.113870
Ishikawa, T., Kageyama, S., Miyahara, Y., Okayama, T., Kokura, S., Wang, L., Sato, E., Yagita, H., Itoh, Y., & Shiku, H. (2021). Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients. Cancer Immunology, Immunotherapy 2021 70:11, 70(11), 3081–3091. https://doi.org/10.1007/S00262-021-02892-W
John D; WICK, M. R. (2018). The American Cancer Society’s Principles of Oncology. The American Cancer Society’s Principles of Oncology. https://doi.org/10.1002/9781119468868
Kaur Sarhadi, V., Daddali, R., Seppänen-Kaijansinkko, R., Pathogenesis, O., Klimczak, A., Kaltschmidt, C., & Mertzlufft, F. (2021). Mesenchymal Stem Cells and Extracellular Vesicles in Osteosarcoma Pathogenesis and Therapy. International Journal of Molecular Sciences 2021, Vol. 22, Page 11035, 22(20), 11035. https://doi.org/10.3390/IJMS222011035
Lugowska, I., Teterycz, P., & Rutkowski, P. (2018). Immunotherapy of melanoma. Contemporary Oncology (Poznan, Poland), 22(1A), 61–67. https://doi.org/10.5114/WO.2018.73889
M, P., Y, L., W, G., Z, S., Z, W., & L, L. (2021). Recent Advances in Epigenetics of Macrovascular Complications in Diabetes Mellitus. Heart, Lung & Circulation, 30(2), 186–196. https://doi.org/10.1016/J.HLC.2020.07.015
MA, A., C, E.-B., MH, E., YO, E., M, M., D, J., TS, A. S., F, K., C, M., E, M., I, O., N, D., & AH, E. (2020). Novel therapeutic strategies for spinal osteosarcomas. Seminars in Cancer Biology, 64, 83–92. https://doi.org/10.1016/J.SEMCANCER.2019.05.018
Marcião, L. G. de A., Sousa, V. N. F. de, Lima, P. E., Lima, L. H. C., Marcião, E. F., Alves, E. L. C., Lira, J. V. M., Moura, L. F. de, Olivetto, M. M. S., Silva, G. da, Ferreira, O. P. C., Rodrigues, A. G., Alves, C. P., Viana, J. B., & Alencar, I. de. (2021). A importância da atenção Fisioterapêutica nos cuidados paliativos em pacientes com câncer. Research, Society and Development, 10(6), e46310616042. https://doi.org/10.33448/rsd-v10i6.16042
Martin, N. T., & Bell, J. C. (2018). Oncolytic Virus Combination Therapy: Killing One Bird with Two Stones. Molecular Therapy, 26(6), 1414–1422. https://doi.org/10.1016/J.YMTHE.2018.04.001
MF, W., LM, W., & TP, C. (2018). Immunotherapy for osteosarcoma: Where do we go from here? Pediatric Blood & Cancer, 65(9). https://doi.org/10.1002/PBC.27227
Misaghi, A., Goldin, A., Awad, M., & Kulidjian, A. A. (2018). Osteosarcoma: a comprehensive review. SICOT-J, 4. https://doi.org/10.1051/SICOTJ/2017028
Miwa, S., Shirai, T., Yamamoto, N., Hayashi, K., Takeuchi, A., Igarashi, K., & Tsuchiya, H. (2019). Current and Emerging Targets in Immunotherapy for Osteosarcoma. Journal of Oncology, 2019. https://doi.org/10.1155/2019/7035045
Mutsaers, A. J., & Walkley, C. R. (2014). Cells of origin in osteosarcoma: mesenchymal stem cells or osteoblast committed cells? Bone, 62, 56–63. https://doi.org/10.1016/J.BONE.2014.02.003
Saba, K. H., Cornmark, L., Rissler, M., Fioretos, T., Åström, K., Haglund, F., Rosenberg, A. E., Brosjö, O., & Nord, K. H. (2019). Genetic profiling of a chondroblastoma-like osteosarcoma/malignant phosphaturic mesenchymal tumor of bone reveals a homozygous deletion of CDKN2A, intragenic deletion of DMD, and a targetable FN1-FGFR1 gene fusion. Genes, Chromosomes & Cancer, 58(10), 731–736. https://doi.org/10.1002/GCC.22764
Sadykova, L. R., Ntekim, A. I., Muyangwa-Semenova, M., Rutland, C. S., Jeyapalan, J. N., Blatt, N., & Rizvanov, A. A. (2020). Epidemiology and Risk Factors of Osteosarcoma. Cancer Investigation, 38(5), 259–269. https://doi.org/10.1080/07357907.2020.1768401
Tadano, H., Tsukahara, T., Mizushima, E., Akamatsu, A., Watanabe, K., Nojima, I., Kubo, T., Kanaseki, T., Hirohashi, Y., Sato, N., & Torigoe, T. (2020). Development of an artificial antibody specific for HLA/peptide complex derived from cancer stem-like cell/cancer-initiating cell antigen DNAJB8. British Journal of Cancer 2020 123:9, 123(9), 1387–1394. https://doi.org/10.1038/s41416-020-1017-1
Verheust, C., Goossens, M., Pauwels, K., & Breyer, D. (2012). Biosafety aspects of modified vaccinia virus Ankara (MVA)-based vectors used for gene therapy or vaccination. Vaccine, 30(16), 2623–2632. https://doi.org/10.1016/J.VACCINE.2012.02.016
Vreeland, T. J., Clifton, G. T., Hale, D. F., Chick, R. C., Hickerson, A. T., Cindass, J. L., Adams, A. M., Bohan, P. M. K., Andtbacka, R. H. I., Berger, A. C., Jakub, J. W., Sussman, J. J., Terando, A. M., Wagner, T., Peoples, G. E., & Faries, M. B. (2021). A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma: A Primary Analysis. Annals of Surgical Oncology, 28(11), 6126–6137. https://doi.org/10.1245/S10434-021-09709-1/FIGURES/3
Wang, S. D., Li, H. Y., Li, B. H., Xie, T., Zhu, T., Sun, L. L., Ren, H. Y., & Ye, Z. M. (2016). The role of CTLA-4 and PD-1 in anti-tumor immune response and their potential efficacy against osteosarcoma. International Immunopharmacology, 38, 81–89. https://doi.org/10.1016/J.INTIMP.2016.05.016
Watanabe, N., McKenna, M. K., Rosewell Shaw, A., & Suzuki, M. (2021). Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment. Molecular Therapy, 29(2), 505–520. https://doi.org/10.1016/J.YMTHE.2020.10.023
Y, Z., N, S., TT, C., O, K., RL, B., YB, M., HS, L., ES, K., & SS, W. (2020). Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103 + conventional dendritic cells. Journal for Immunotherapy of Cancer, 8(1). https://doi.org/10.1136/JITC-2019-000474
Yalçın, S., Yalçınkaya, S., & Ercan, F. (2021). In silico detection of inhibitor potential of Passiflora compounds against SARS-Cov-2(Covid-19) main protease by using molecular docking and dynamic analyses. Journal of Molecular Structure, 1240. https://doi.org/10.1016/J.MOLSTRUC.2021.130556
Younis, J., al Antably, I., Zamzam, M., Salem, H., Zaki, E., & Hassanian, O. (2019). Role of 18 F-fluorodeoxyglucose positron emission tomography/computed tomography and magnetic resonance imaging in prediction of response to neoadjuvant chemotherapy in pediatric osteosarcoma. World Journal of Nuclear Medicine, 18(4), 378. https://doi.org/10.4103/WJNM.WJNM_52_18
Zhang, Y., Yang, J., Zhao, N., Wang, C., Kamar, S., Zhou, Y., He, Z., Yang, J., Sun, B., Shi, X., Han, L., & Yang, Z. (2018). Progress in the chemotherapeutic treatment of osteosarcoma. Oncology Letters, 16(5), 6228. https://doi.org/10.3892/OL.2018.9434
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Tatiane Batista dos Santos; Denilson dos Santos Gomes; Alícia Beatriz Fontes de Sousa ; Ítalo Samuel Gonçalves Rodrigues; Francine Ferreira Padilha; Daniela Droppa-Almeida
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
